» Articles » PMID: 19541744

Structural and Functional Characterization of the Interdomain Interaction in the Mineralocorticoid Receptor

Overview
Journal Mol Endocrinol
Date 2009 Jun 23
PMID 19541744
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

The mineralocorticoid receptor (MR) plays a central role in electrolyte homeostasis and in cardiovascular disease. We have previously reported a ligand-dependent N/C-interaction in the MR. In the present study we sought to fully characterize the MR N/C-interaction. By using a range of natural and synthetic MR ligands in a mammalian two-hybrid assay we demonstrate that in contrast to aldosterone, which strongly induces the interaction, the physiological ligands deoxycorticosterone and cortisol weakly promote the interaction but predominantly inhibit the aldosterone-mediated N/C-interaction. Similarly, progesterone and dexamethasone antagonize the interaction. In contrast, the synthetic agonist 9alpha-fludrocortisol robustly induces the interaction. The ability of the N/C interaction to discriminate between MR agonists suggests a subtle conformational difference in the ligand-binding domain induced by these agonists. We also demonstrate that the N/C interaction is not cell specific, consistent with the evidence from a glutathione-S-transferase pull-down assay, of a direct protein-protein interaction between the N- and C-terminal domains of the MR. Examination of a panel of deletions in the N terminus suggests that several regions may be critical to the N/C-interaction. These studies have identified functional differences between physiological MR ligands, which suggest that the ligand-specific dependence of the N/C-interaction may contribute to the differential activation of the MR that has been reported in vivo.

Citing Articles

The mineralocorticoid receptor forms higher order oligomers upon DNA binding.

Fettweis G, Johnson T, Almeida-Prieto B, Weller-Perez J, Presman D, Hager G Protein Sci. 2023; 33(3):e4890.

PMID: 38160317 PMC: 10868434. DOI: 10.1002/pro.4890.


Aldosterone: Renal Action and Physiological Effects.

Johnston J, Welch A, Cain B, Sayeski P, Gumz M, Wingo C Compr Physiol. 2023; 13(2):4409-4491.

PMID: 36994769 PMC: 11472823. DOI: 10.1002/cphy.c190043.


Brain mineralocorticoid receptor in health and disease: From molecular signalling to cognitive and emotional function.

Paul S, Wingenfeld K, Otte C, Meijer O Br J Pharmacol. 2022; 179(13):3205-3219.

PMID: 35297038 PMC: 9323486. DOI: 10.1111/bph.15835.


Steroid Receptors in Breast Cancer: Understanding of Molecular Function as a Basis for Effective Therapy Development.

Kowalczyk W, Waliszczak G, Jach R, Dulinska-Litewka J Cancers (Basel). 2021; 13(19).

PMID: 34638264 PMC: 8507808. DOI: 10.3390/cancers13194779.


Glucocorticoid receptor Thr524 phosphorylation by MINK1 induces interactions with 14-3-3 protein regulators.

Munier C, De Maria L, Edman K, Gunnarsson A, Longo M, Mackintosh C J Biol Chem. 2021; 296:100551.

PMID: 33744286 PMC: 8080530. DOI: 10.1016/j.jbc.2021.100551.


References
1.
Rupprecht R, Arriza J, Spengler D, Reul J, Evans R, Holsboer F . Transactivation and synergistic properties of the mineralocorticoid receptor: relationship to the glucocorticoid receptor. Mol Endocrinol. 1993; 7(4):597-603. DOI: 10.1210/mend.7.4.8388999. View

2.
Zoppi S, Wilson C, Harbison M, GRIFFIN J, Wilson J, McPhaul M . Complete testicular feminization caused by an amino-terminal truncation of the androgen receptor with downstream initiation. J Clin Invest. 1993; 91(3):1105-12. PMC: 288066. DOI: 10.1172/JCI116269. View

3.
Joels M, Karst H, DeRijk R, de Kloet E . The coming out of the brain mineralocorticoid receptor. Trends Neurosci. 2007; 31(1):1-7. DOI: 10.1016/j.tins.2007.10.005. View

4.
He B, Kemppainen J, Wilson E . FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor. J Biol Chem. 2000; 275(30):22986-94. DOI: 10.1074/jbc.M002807200. View

5.
Miner J, Chang W, Chapman M, Finn P, Hong M, Lopez F . An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate. Endocrinology. 2006; 148(1):363-73. DOI: 10.1210/en.2006-0793. View